The primary aim of the present trial was to compare the effects of liraglutide 1.8 and 3.0 mg, the maximum approved dose in treatment of type 2 diabetes and the intended clinical dose in weight management, respectively, on gastric emptying in obese individuals without T2DM, with the focus on demonstrating equivalence between the two doses over a 5-h period, in order to support that no dose adjustment of concomitantly administered oral medications would be required during treatment with liraglutide 3.0 mg
An extensive menu of obesity drugs that work via distinct biological mechanisms means that patients will have more options to try
Most of these problems happen in your stomach and digestive system
Protecting muscle matters more than adherence to a fasting protocol
Patients experiencing persistent systemic symptoms should be evaluated for other causes, including intercurrent illness or dehydration
However, because of the preliminary nature of these studies, the overall rating was C due to limited evidence, although one double-blind placebo-controlled study using NAC in human lead exposure was promising